Cowen downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Outperform to Market ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Downgrades Hot Downgrades

Sarepta Therapeutic (SRPT) PT Cut to $38 at Needham & Company; 'Buy' MaintainedMarch 2, 2015 8:43 AM Baird Maintains Neutral View on Sarepta Therapeutic (SRPT) Post Q4February 27, 2015 9:07 AM Sarepta Therapeutics (SRPT) Posts Wider Q4 Loss; NDA Submission for Eteplirsen Planned for Mid-Year 2015February 26, 2015 7:07 AM